Oncorus is a pre-clinical stage biotechnology company developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit all arms of immune system to treat solid tumors.
The Oncorus family is dedicated to bringing hope and impactful therapies to cancer patients everywhere. As part of our commitment, we have taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $141.99M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | SV Investm... | svinvest.c... |
| - | K2 HealthV... | k2healthve... |
| - | BioImpact ... | bioimpactc... |
| - | Perceptive... | perceptive... |
| - | UTC Invest... | utc.co.kr |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.08.2019 | Series B | $80M | Perceptive... |
| 16.12.2016 | Series A | $4.99M | - |
| 20.07.2016 | Series A | $57M | - |
Mentions in press and media 17
| Date | Title | Description | Source |
| 05.04.2022 | Oncorus Announces Debt Capital Facility with K2 HealthVentur... | -Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use ... | globenewsw... |
| 27.05.2021 | ONCORUS, INC. Oncorus Announces Nomination of its First IV-... | Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for onc... | marketscre... |
| 21.08.2019 | Oncorus raises $80M for 2-front oncolytic virus R&D push... | Oncorus has raised $79.5 million to advance oncolytic viruses. The series B round equips Oncorus to ... | fiercebiot... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Funding | CAMBRIDGE, MA, Oncorus today announced the completion of an oversubscribed $79.5 million Series B ... | vcnewsdail... |
| 21.08.2019 | Oncorus Raises $79.5M in Series B Financing | Oncorus, Inc., a Cambridge, Mass.-based oncolytic virus company, closed a $79.5m Series B financing.... | finsmes.co... |
| 21.08.2019 | Oncorus Announces $79.5 Million Series B Financing Co-Led by... | –Company advancing broad pipeline of next-generation oncolytic virus therapies for both intratumoral... | venturebea... |
| 21.08.2019 | Oncorus Announces $79.5 Million Series B Financing to Suppor... | - | mpmcapital... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Hea... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving inno... | citybizlis... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Hea... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving inno... | archive.ci... |
| 21.08.2019 | Oncorus raises $80M for 2-front oncolytic virus R&D push | Oncorus has raised $79.5 million to advance oncolytic viruses. The series B round equips Oncorus to ... | fiercebiot... |
Show more